Quotient announces extension of RapidFACT™ into non-oral routes of delivery

Nottingham, U.K, (19th March 2013) –Quotient Clinical, part of Quotient Bioresearch (“Quotient”) today announced that three new pharma and biotech clients have selected its RapidFACT™ service to support the development of optimal drug products for pulmonary, transdermal, and ocular administration.  This marks a key extension in the application of RapidFACT™ across a wide range of dosage forms and delivery routes.

RapidFACT™  (Rapid Formulation development And Clinical Testing) is underpinned by a Translational Pharmaceutics platform that integrates formulation development, “real-time” GMP product manufacturing, and clinical testing. Compared to conventional development processes, RapidFACT™ shortens development timelines, lowers costs, and also reduces the consumption of drug substance by up to 90%.

Mark Egerton, Managing Director of Quotient Clinical, said:

“We are delighted that RapidFACT™ has been selected to support the development of these exciting new products. To date, RapidFACT™ has been deployed on over 30 programs that have focused on oral delivery or intranasal delivery. These new programs further demonstrate the broad utility of RapidFACT™ and our belief that it can be used to support the development of molecules for any route of delivery.”

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.